Bayer HealthCare

Transcription

1 Bayer HealthCare Open Innovation Initiatives at Bayer and the Berlin CoLaborator. Dr. Jörg Knäblein, Technology Scouting Global External Innovation & Alliances, Global Drug Discovery 16 Sep 2015, FORUM Companion Diagnostics, CoLaborator

2 The focus of our R&D is on delivering innovative drug candidates to meet the needs of the patients. In that context, complementing our own capabilities with innovative partners from academia and biotech companies plays an important role... Prof. Andreas Busch Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery, Bayer HealthCare Source: quote on flyer for BIO-Europe 2014 Page 2

3 Agenda BHC Pharmaceuticals Why partnerships are needed to complement our strong internal research Partnering models along the value chain CoLaborator in Berlin Conclusions Page 3

4 Bayer HealthCare Pharmaceuticals Drug Discovery at a Glance Berlin Wuppertal / Cologne / Monheim Berkeley / San Francisco Turku Oslo Oncology Gynecological Therapies Cross Indication Platform Cardiovascular Diseases Ophthalmology Biologics Research & Development Cross Indication Platform Animal Health Research Hematology Biologics Research & Development Chemical and Pharmaceutical Development: Polymer-based Drug Delivery Systems Oncology: Thorium Conjugates Platform Investment in R&D 2014: 2,3 billion R&D Employees 2014: Page 4

5 Bayer HealthCare Pharmaceuticals Research Focus Hematology Cardiovascular Diseases Thrombosis / Heart Failure / Acute Coronary Syndrome Kidney Diseases Lung Diseases Hemophilia Rare Bleeding Disorders / Acute Bleeding Hemoglobinopathies Hematopoiesis Gynecological Therapies Oncology Cell Cycle / Survival Signaling Tumor Metabolism / Chromatin Biology Immunotherapies / Antibody- Drug Conjugates / Thorium Conjugates Endometriosis Uterine Fibroids Ophthalmology Macular degeneration Other Exsudative / Non- Exsudative Eye Diseases Page 5

6 Innovations for our Patients Launch in first/main indication Rivaroxaban Regorafenib Aflibercept Radium-223 dichloride Riociguat Anticoagulation: Improving quality of life for wide range of patients; oral, no monitoring, no dietary restrictions Gastrointestinal stromal tumors: Highly significant progression free survival benefit Wet age-related macular degeneration: Maintaining or even improving visual acuity Bone metastases in prostate cancer: Extending survival, improving quality of life, being well tolerated Pulmonary hypertension: The first and only treatment with sustained clinical efficacy in two types of severe pulmonary hypertension Combined* Peak Sales Potential > 7.5 bn *Combined peak sales potential for Xarelto, Stivarga, Eylea, Xofigo and Adempas assuming approvals and launches planned Page 6

7 Probability of success from research to market approval: <1% Drug research Preclinical Clinical trials Evaluation/ Approval Phase IV studies Lab and animal experiments Phase I: healthy volunteers Phase II: patients safety, dosing Phase III: 1,000-10,000 patients efficacy, adverse events Data review by regulatory authorities (up to 2 years) (more than 2 years) 10,000 Test compounds <250 Test compounds <5 Test compounds 1 drug approved by health authorities >1 billion Years Source: based on PhRMA Profile Pharmaceutical Industry 2010 Page 7

8 Challenges in biomedical R&D Need Proof of true innovation with added value in comparison to standard of care Basic understanding of (molecular) mechanisms of diseases Predictive models Companies only represent a small portion of the biomedical knowledge Biomedical R&D spending p.a. global BHC Biomarker for patient stratification and treatment monitoring New regulatory framework >250 Billion 2 Billion Partnerships with all relevant groups as a key to success Page 8

9 A wide range of flexible models provides the right fit to our partners Idea for a Collaboration Partner Model Strategic Alliance Consortium Joint lab Outsourcing Crowdsourcing Incubator VC Investment Licensing* Examples Broad Institute (2013, 2015) OncoMed (2010) Peking University (2014) Innovative Medicines Initiative, SGC DKFZ (2008) Pharmaron, WuXi Grants4Targets (2009) Grants4Leads (2013) CoLaborator Mission Bay (2012) Berlin (2014) Versant Ventures (2013), HTGF (2013) PSMA BiTE, FXIa Ab Flexibility Criteria Involvement, Investment/Size, # of Projects, # of Partners, Duration, Partner * BD&L is responsible for most licensing projects Page 9

10 External Innovation & Alliances is an Integrated Part of Global Drug Discovery Global External Innovation & Alliances is part of BHC Global Drug Discovery Global External Innovation & Alliances focuses on: Development & management of strategic alliances & open innovation initiatives Research policy and public funding Strategic outsourcing Local Hubs: Innovation Center China Science Hub US Science Hub Singapore San Francisco Headquarters Berlin Beijing Singapore Global External Innovation & Alliances is responsible for research partnering activities of Bayer HealthCare-Global Drug Discovery Page 10

11 The components of the CoLaborator concept Components Support young entrepreneurs in the Life Science area to build up their own research laboratories. Companies with a fit of interest with Bayer can rent ready-to-use laboratories with the potential to combine startup entrepreneurship with pharma expertise. Companies remain independent but have an option to use the Bayer infrastructure and scientific network. Page 11

12 CoLaborator in San Francisco The first CoLaborator was inaugurated in September 2012 in San Francisco/ Mission Bay in the same building as our research laboratories. Page 12

13 CoLaborator in Berlin On the Bayer Campus in Berlin Close vicinity to well renowned institutions Berlin offers attractive ecosystem for startups Page 13

14 The CoLaborator Berlin Technical environment 800 qm building with 9 fully equipped units consitent of a laboratory (40 qm) plus office (20 qm) Shared facilities (Cafeteria, meeting room, cooling room, etc.) Bayer offers a range of services on demand Scientific environment: Exchange amongst CoLab tentants plus with Bayer scientists and experts Protection of intellectual property warranted by agreements if nessecary. Page 14

15 Berlin CoLaborator (status as of ) Company Profiles CoLaborator Companies Calico GmbH (04/2014; biomarker and biotherapeutics): offers innovative methods to develop recombinant monoclonal antibodies to engineer both biotherapeutics as well as biomarker products. All aspects of cell biology, DNA cloning, protein engineering and diagnostic pathology DexLeChem GmbH (04/2014; chemical synthesis): founded out of the Cluster of Excellence UniCat (Unifying Concepts in Catalysis), is developing catalytic hydrogenolysis in water. Specialized in chemical engineering, chiral catalysis and quantum physics Eternygen GmbH (09/2014; dietary-related metabolic diseases): is focusing on research and development targeting the transporter protein SLC13A5. Research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity NMI TT Pharmaservices (01/2015; multiplexed protein expression and analysis of cellular signal transduction pathways): is a CRO dedicated to provide integrated experts services to the pharmaceutical industry, as well as to biotechnical and medical technology companies. Novel proprietary multiplexed protein expression and analysis of cellular signal transduction pathways is performed on a highly reliable Western-Blot like assay for biomarker screening (DigiWest ) Page 15 Provitro AG (04/2014; biomarker and molecular-pathology): is an innovative molecularpathological service provider for preclinical and clinical research in pharmacology and biotechnology. Principal business area is based on a well-stocked tissue bank and close scientific cooperation with Charité University Hospital Berlin

16 Open innovation is an important part of our partnering strategy Idea for a Collaboration Partner Model Strategic Alliance Consortium Joint lab Outsourcing Crowdsourcing Incubator VC Investment Licensing* Examples Broad Institute (2013, 2015) OncoMed (2010) Peking University (2014) Innovative Medicines Initiative, SGC DKFZ (2008) WuXi Apptech Grants4Targets (2009) Grants4Leads (2013) CoLaborator Mission Bay (2012) Berlin (2014) Versant Ventures (2013) HTGF (2013) PSMA BiTE, FXIa Ab Flexibility Criteria Involvement, Investment/Size, # of Projects, # of Partners, Duration, Open Innovation- Initiatives * BD&L is responsible for most licensing projects Page 16

17 Bayer Open Innovation Family Grants4Targets Grants4Leads Grants for targets and biomarkers. Grants to assess small molecule leads Grants for innovative IT projects which may lead to new business models. Identifying and developing novel drugs (including antibodies and antibody derivatives) ets.com ds.com s.com odies.bayer.com/ Page 17

18 Conclusions Bayer is committed to innovation: Science for a Better Life Partnering complementing internal excellence is a key to success for addressing the challenges in healthcare There is no one-size-fits-all solution; for each goal the right partnering model has to be found Governance structure of alliances should include professional alliance management from the beginning The organizational setup can support the partnering activities Berlin CoLaborator is an important member of the BHC Open Innovation Family Page 18

19 It s all about people Page 19

20 Thank you! Page 20

21 Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 21

22 TECHNOLOGY SCOUTING (TS) we serve your needs Dr. Jörg Knäblein TECHNOLOGY SCOUTING Bayer HealthCare Pharmaceuticals; Berlin, S105, 05, 525 Phone: ; Fax: Mobile: Web: Page , joerg.knaeblein@bayer.com

23 TS knows internal needs due to close interaction with BHC community utilized sources come from personal contacts TS is complementary to other Innovation Sourcing activities value add is focus on terra incognita (unpublished) Scope: Source, identify & evaluate valuable Tech Offers / ASSETS (compounds, biomarker, animal models, cells, biospecimens, targets, technologies, co-operations, projects) from academic groups world wide Clients: Internal customers are from all indications & all sites: GTRGs, CG&EI, ER groups, BUs, but also GD; plus special requests from GPTs asking for specific (external) support Source: academia industry TS addresses Innovation Gap : maturity, communication, and confidence Conferences / Active Role Networking / Personal Contacts Reach Out / Efficient Trips Educational Advertising / Trustful Scientist Leverage Internal Resources External key sources are academic research institutes, universities, TTOs, bioregions, databases, newsletters, publications, meetings, site-visits, conferences and personal communication Page 23

24 Unique Selling Proposition of TS is access to ASSETS not yet published enabled by global network of personal contacts ASSETS Trust & scientific acceptance ASSETS from invisible terra incognita Evolution of scouting strategy passive active proactive focused visible receiving offers screen databases ask TTOs Focused Scouting: specific requests at personal contacts yield maximum ASSETS Focused search in continuously extended network. Ask for specific technologies at appropriate partners. Follow-up with experts for other possible sources. Rely on trustful working relation, built over years. specific request invisible terra incognita t Page 24

25 TS communication / interfaces essential to get ASSETS: Tell sources what BHC needs and BHC what sources have Sources/Offers BHC Needs Research institutes Universities / TTOs Databases / conferences pull push GDD Technology Scouting pull push ER groups, GTRGs BUs, GPTs, Individual requests External: TS presentation Summary of what BHC needs Continuously updated Specific requests included Internal: Team Rooms (PIx) Target-specific repositories Presentation at ER meetings Jour fixes with functions Page 25 Bayer BHC what s needed USA GBD&L multiplier CANADA JAPAN ROW AH NBV BUs identifier what s needed & what we have

26 > Tech Offers TS uses precise, continuously updated, and very tight selection criteria to identify ASSETS: all indications, all categories, all sites Technology Scouting has the lead during entire process, supported by several functions Rigorous filtering (e.g. 98% One) yields in valuable Tech Offers ASSETS Filter One: Filter Two: Filter Three: precise & tight criteria Technology Scouting selected by BU/Functions Partner: ER groups, individuals acceptable conditions (e.g. resources) & sponsor Partner: Legal, (EL), Procurement Finalize Contract used by business partners ** Team Rooms (PIx) ASSETS WIP * in-house Animal Models Biomarker/ -Banks Cell Lines Compounds Projects / targets Technologies ONC GYN CAR HEM ** assets provided to business partners (GTRGs, MedChem, LD, GBM, GED, GB, CS, AH, GBD&L, etc.) are essential to support achievement of milestones and have direct impact on pipeline / Ds Page 26